Disappointing delay for Gensia

Gensia Inc. on Friday said that it had run into a snag in the initial scale-up of its formulation of Geomatrix nifedipine, and that further formulation will be required.

As a result, the San Diego company's ANDA submission for the cardiovascular drug will be delayed beyond the planned first half of 1995. GNSA said it still hopes to file in 1995, although that depends on how quickly successful modifications can be made...